Joe Y. Chang/X
Jun 6, 2025, 06:22
Joe Y Chang Shared PTCOG 2025 Phase III Data on IMPT vs. IMRT in Head and Neck Cancer
Joe Y Chang, Professor and Clinical Section Chief at MD Anderson Cancer Center, shared a post on X:
“First phase III randomized study showed an improvement in overall survival with proton-based IMPT compared to photon IMRT in head and neck cancer.
This was presented today during the The Particle Therapy Co-Operative Group (PTCOG) plenary session by Steven J. Frank.
The exciting data provides justification for IMPT.”
More posts featuring Joe Y Chang on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 16:46
Aug 8, 2025, 16:41
Aug 8, 2025, 16:31
Aug 8, 2025, 16:11
Aug 8, 2025, 15:57
Aug 8, 2025, 15:54
Aug 8, 2025, 15:49